On this page you can find relevant researchs on drug-related health topics, including HIV, hepatitis C, drug and overdose prevention, harm reduction and drug treatment. You can also find our Clinical Guidelines.

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence?
A simulation model for the UK and other countries was used to estimate the impact on the spread of hepatitis C virus of scaling-up opiate substitution therapy and high coverage needle and syringe programmes.
Improving targeted screening for Hepatitis C in the UK
BMJ editorial on the important role that primary care practitioners can play in improving targeted screening for Hepatitis
IDHDP newsletter - September 2012
This issue highlights IDHDP activities, upcoming conferences, new publications, and more.
SMMGP Clinical Update August-September 2012
This document produced by SMMGP gives an update on current clinical documents for August and September 2012.
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis
A study which quantifies the effect of opiate substitution treatment in relation to HIV transmission among people who inject drugs.
EHRN newsletter : The voice of harm reduction
This edition of the newsletter is focused on the topic of overdose
The economic impact of Hepatitis C in Australia
Hepatitis Australia highlights that investment in new hepatitis C treatment will cure more people of a chronic and costly condition and provide substantial economic benefits for society in the long term.
Prevalence of common chronic respiratory diseases in drug misusers: a cohort study
This study demonstrates increased respiratory disease in people who use drugs, but the structure of this study could under-report the respiratory issues in people receiving care in specialised substance misuse or shared care clinics.
European Monitoring Centre on Drugs and Drug Addiction strategy and work programme 2013-2015
The 2013–15 strategy is built around three top-level commitments: (a) providing a relevant, timely and responsive analysis of the drug situation; (b) efficiency: deriving maximum value from activities and investments; (c) communication and a customer-orientated approach.
Share this on: